Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype
Howard Gurney(Radboud University Nijmegen), Horst Schran(Novartis (Switzerland)), Andrew J. McLachlan(The University of Sydney), Christine L. Clarke(Memorial University of Newfoundland), Kevin Lynch(Ollscoil na Gaillimhe – University of Galway), Nicholas Wilcken(Westmead Hospital), Michael D. Collins(Westmead Hospital), Rosemary L. Balleine(The University of Sydney), Graham J. Mann(Murdoch University), S-E Delforce(Westmead Hospital), Ma‐Li Wong(SUNY Upstate Medical University), Janelle M. Hoskins(University of North Carolina at Chapel Hill), Laurent P. Rivory(The University of Sydney)
Cited by 142
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
|Journal of Clinical Epidemiology|2012|1.2k